News
Why One-Size Cannabis Limits Fail Medical Patients
Add MyCannabis.com to your preferred sources on Google
Cannabis research is entering a new phase, one that increasingly mirrors how society approaches alcohol, prescription medications, and other regulated substances. A newly published, peer-reviewed study1 from researchers at the University of Bath, appearing in the journal Addiction, proposes standardized “THC units” to help define safer levels of cannabis use. The goal is harm reduction: helping consumers, clinicians, and public health officials better understand how potency and quantity interact to affect health risks.
At first glance, this research represents progress. For decades, cannabis users, especially medical patients, have been navigating dosing with little guidance, inconsistent labeling, and a policy environment that often treats all use as inherently problematic. However, as this study gains traction, it also raises an urgent question: can we responsibly apply population-level cannabis limits to a plant that functions as medicine for millions of people?
The answer, many advocates argue, is no, at least not without nuance, context, and patient-centered framing. Let’s dive in.
What the University of Bath Study Proposes
The Bath researchers suggest measuring cannabis consumption using standardized THC units, similar to alcohol units used in the UK. Rather than focusing on how often someone uses cannabis, the model emphasizes total THC intake, accounting for both potency and quantity.
Based on data from the CannTeen study, a year-long assessment of cannabis use and cannabis use disorder (CUD) severity, the researchers propose that adults should not exceed 8 THC units per week, roughly equivalent to 40 mg of THC or one-third of a gram of herbal cannabis. Use above this threshold was associated with a higher likelihood of CUD, with risk increasing further beyond 13 units per week.
Dr. Rachel Lees Thorne, lead author of the study, explained the intent clearly:
“The ultimate goal of our new guidelines is to reduce harm. The only truly safe level of cannabis use is no use.”
She continued by emphasizing that the guidelines are intended to support people who choose not to stop using cannabis, offering evidence-based ways to lower potential risks through lower-THC products or reduced quantities.
From a public health perspective, this framing is familiar. Harm reduction strategies often start from a conservative baseline. However, when applied to cannabis, particularly medical cannabis, this statement becomes deeply problematic.
When Harm Reduction Overlooks Medical Reality
Cannabis is not simply a recreational substance. It is a therapeutic agent used by patients with chronic pain, autoimmune disorders, neurological conditions, gastrointestinal diseases, cancer, PTSD, and connective tissue disorders such as Ehlers-Danlos syndrome (EDS).
For many patients, the proposed “safer” threshold of 40 mg of THC per week is not just insufficient; it is also nonfunctional.
Some individuals, including patients with EDS, severe neuropathic pain, or significant inflammatory conditions, may require hundreds or even thousands of milligrams of THC per day to manage symptoms. Importantly, these patients often report little to no intoxicating effect, instead experiencing pain relief, muscle relaxation, improved sleep, and reduced inflammation.
This phenomenon is not anecdotal noise, it reflects tolerance, endocannabinoid system variation, metabolic differences, and disease-driven demand. Applying a blanket statement that equates higher-dose use with inherent risk fails to acknowledge that medical cannabis dosing does not follow recreational logic.
No physician would tell a chronic pain patient that the “only safe level” of opioids, antidepressants, or anti-epileptics is zero. Cannabis should not be treated differently simply because of lingering stigma.
Swipe to scroll →
| Use Context | Typical THC Pattern | Where THC Units Help | Key Limitation |
|---|---|---|---|
| Recreational (new / occasional) | Low frequency, low tolerance | Benchmarking potency, avoiding overuse | Few—population guidance is useful here |
| Recreational (regular) | Moderate frequency, rising tolerance | Tracking escalation, planning reductions | Dose ≠ disorder without functional harm |
| Medical (typical) | Daily, titrated to symptom relief | Consistency, labeling, dose logging | Rigid ceilings ignore individualized dosing |
| Medical (high-need) | Higher daily THC, functional tolerance | Documentation, care coordination | Population limits ≠ medical safety |
Cannabis and the Endocannabinoid System: A Biological Fit
Unlike many pharmaceuticals, cannabis interacts with a system our bodies already possess: the endocannabinoid system (ECS). This regulatory network plays a critical role in maintaining balance across pain signaling, immune response, inflammation, mood, appetite, and sleep.
Cannabinoids such as THC and CBD bind to an array of receptors, helping modulate processes that are often dysregulated in chronic illness. This is why cannabis can be effective across such a wide range of conditions and why dosing needs vary dramatically from person to person.
Beyond symptom management, cannabis compounds demonstrate antioxidant and anti-inflammatory properties that may offer systemic benefits. Research has shown cannabinoids can reduce oxidative stress, modulate immune activity, and protect neural tissue. These effects are not limited to people seeking intoxication; they are part of cannabis’s therapeutic profile.
To state that “no use” is the only safe use fails to acknowledge both biological compatibility and documented benefit.
The Risk of Conflating Use With Disorder
The Bath study focuses heavily on cannabis use disorder, estimating that roughly 22% of regular users may develop problematic use patterns. This is an important area of research, but it must be interpreted carefully.
High-dose use does not automatically equal addiction, just as long-term opioid use under medical supervision does not inherently equal opioid use disorder. Context matters, intent matters, and outcomes matter.
For medical patients, cannabis may increase function, not impair it. It may allow someone to work, sleep, eat, or live without constant pain. Measuring risk solely through consumption thresholds risks pathologizing patients who are using cannabis appropriately and effectively.
Where THC Unit Guidelines Actually Help
Despite these concerns, the Bath study offers meaningful contributions. Standardized THC units could improve labeling, help new consumers understand potency, and support informed decision-making, particularly in newly legal markets.
For recreational users, these guidelines may offer a helpful benchmark. For clinicians unfamiliar with cannabis, THC units could provide a starting framework for discussion. For regulators, standardized measures could improve consistency and transparency.
But these tools must be presented as guides, not rules, and certainly not as moral judgments.
Toward Patient-Centered Cannabis Policy
As cannabis legalization expands globally, the conversation must evolve beyond fear-based thresholds. We need policies and public health messaging that distinguish between recreational use, problematic use, and medical necessity.
Cannabis is not a one dose fits all product, but a complex therapeutic plant.
True harm reduction means acknowledging that some people use cannabis not for escape, but for survival, and that for them, “safe” does not mean abstinence. It means access, education, individualized dosing, and freedom from stigma.
The University of Bath study opens the door to better conversations about cannabis dosing. Now it’s up to advocates, clinicians, and policymakers to ensure those conversations include the voices of patients whose lives are improved, not endangered, by cannabis use.
References:
1. Thorne, R. L., Lawn, W., Petrilli, K., Skumrien, M., Grafenstein, A., Curley, L., … & Freeman, T. P. (2026). Estimating thresholds for risk of cannabis use disorder using standard delta-9-tetrahydrocannabinol (THC) units. Addiction. Advance online publication. https://doi.org/10.1111/add.70263
